<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01474512</url>
  </required_header>
  <id_info>
    <org_study_id>12972</org_study_id>
    <secondary_id>I1F-MC-RHAZ</secondary_id>
    <nct_id>NCT01474512</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study in Participants With Moderate to Severe Psoriasis</brief_title>
  <acronym>UNCOVER-1</acronym>
  <official_title>A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of LY2439821 compared to placebo in
      participants with moderate to severe, chronic plaque psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)</measure>
    <time_frame>Week 12</time_frame>
    <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of &quot;0&quot; or &quot;1&quot; with at least a 2-point improvement from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving ≥75% Improvement in Ps Area and Severity Index (PASI75) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis Measure: PASI)</measure>
    <time_frame>Week 12</time_frame>
    <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an sPGA of 0 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)</measure>
    <time_frame>Week 12</time_frame>
    <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving PASI 90% (PASI90) or 100% (PASI100) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: PASI)</measure>
    <time_frame>Week 12</time_frame>
    <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI90 or PASI100 were defined as having an improvement of ≥90% or of 100% respectively in PASI scores compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Maintaining sPGA 0 or 1 After Re-Randomization at Start of Maintenance Dosing Period</measure>
    <time_frame>Week 60</time_frame>
    <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Itch Numeric Rating Scale (Itch NRS) Score ≥4 Point Reduction From Baseline</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dermatology-Specific Quality of Life Index (DLQI) Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered (&quot;not relevant&quot;) responses were scored as &quot;0.&quot; Total scores range from 0 to 30, with higher score indicating greater quality of life is impairment. A 5-point change from baseline is considered clinically relevant. Least squares (LS) mean change from baseline was calculated using mixed model repeated measures (MMRM).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nail Psoriasis Severity Index (NAPSI)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail Ps. This scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants of the matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, then the sum of all fingernails equals the total NAPSI score with a range from 0 to 80 with higher scores indicating more severe psoriasis. LS mean change from baseline was calculated using MMRM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Body Surface Area (BSA) Involvement of Ps</measure>
    <time_frame>Week 12</time_frame>
    <description>BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), where 1% corresponds to the size of the participants hand (includes the palm, fingers and thumb). Total BSA is the sum of handprints from the affected areas. LS mean change from baseline was calculated using MMRM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Psoriasis Scalp Severity Index (PSSI)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (&lt;10%) to 6 (90%-100%) with a total scores range from 0 to 72, with lower scores indicating less severity. LS mean change from baseline was calculated using MMRM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO) (Quality of Life and Outcome Assessments. Measures: Participant Reported Outcomes [PRO])</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>WPAI-PSO is a participant administered, 6-item instrument used to assess the impact of Ps on the productivity impairment within the past 7 days. WPAI-PSO has 4 domains: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism (reduced productivity while at work), overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as: each score * 100 with greater scores indicating greater impairment. LS mean change from baseline was calculated using analysis of covariance (ANCOVA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Reported 16 Items (QIDS-SR16)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst). The sum of the 16 items corresponding to 9 depression domains [sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity. LS mean change from baseline was calculated using ANCOVA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Medical Outcomes Study 36-item Short Form Health Survey (SF-36) and Physical Component Summary (PCS) and Mental Component Summary (MCS)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The SF-36 is a self-reported instrument that measures the participant's health status during the previous 7 days. It comprises 36-items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped in the PCS and MCS scores. Scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean change from baseline was calculated using ANCOVA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Global Assessment of Disease Severity (PatGA)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis &quot;today&quot; by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been). LS mean change from baseline calculated using MMRM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Palmoplantar PASI (PPASI) of ≥50% (PPASI50), ≥75% (PPASI75), or 100% (PPASI100) Improvement</measure>
    <time_frame>Week 12</time_frame>
    <description>The Palmoplantar PASI is a composite score derived from the sum of scores for erythema, induration, and desquamation [scores range from 0 (none) to 4 (very severe) for each] multiplied by the score for the extent of palm and sole area involvement [scores range from 0 (0%) to 6 (90 to100%)], with a total scores range from 0 to 72. Participants achieving PPASI50, PPASI75 or PASI100 were defined as having an improvement of at least 50%, 90%, or of 100%, respectively, in the PPASI scores compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Trough Concentration at Steady State (Ctrough ss)</measure>
    <time_frame>Weeks 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-ixekizumab Antibodies</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants * 100%.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1296</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered as two 80-mg subcutaneous (SC) injections at Week 0, then one 80-mg SC injection per Dosing Regimen 1 [every 2 weeks (Q2W)] up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 [every 4 weeks (Q4W)] or Dosing Regimen 3 [every 12 weeks Q12W)].</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered as two 80-mg SC injections at Week 0, then one 80-mg SC injection per Dosing Regimen 2 (Q4W) up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 (Q4W) or Dosing Regimen 3 (Q12W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 mg Ixekizumab Dosing Regimen 3 (Q12W)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing Regimen 3 (Q12W) is not used until Week 12. At Week 12, participants who were re-randomized to this arm were administered one 80-mg SC injection Q12W.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered as 2 SC injections at Week 0, then 1 SC injection per Dosing Regimen 1 (Q2W) up to and including Week 10. At Week 12, arm is re-randomized to placebo or Dosing Regimen 2 (Q4W).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>80 mg Ixekizumab Dosing Regimens 1, 2, and 3</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W)</arm_group_label>
    <arm_group_label>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</arm_group_label>
    <arm_group_label>80 mg Ixekizumab Dosing Regimen 3 (Q12W)</arm_group_label>
    <other_name>LY2439821</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Present with chronic plaque psoriasis based on a confirmed diagnosis of chronic
             psoriasis vulgaris for at least 6 months prior to randomization

          -  At least 10% Body Surface Area (BSA) of Psoriasis at screening and at randomization

          -  Static Physician Global Assessment (sPGA) score of at least 3 and Psoriasis Area and
             Severity Index (PASI) score of at least 12 at screening and at randomization

          -  Candidate for phototherapy and/or systemic therapy

          -  Men must agree to use a reliable method of birth control during the study

          -  Women must agree to use birth control or remain abstinent during the study and for at
             least 12 weeks after stopping treatment

        Exclusion Criteria:

          -  Pustular, erythrodermic, and/or guttate forms of psoriasis

          -  History of drug-induced psoriasis

          -  Clinically significant flare of psoriasis during the 12 weeks prior to randomization

          -  Concurrent or recent use of any biologic agent

          -  Received systemic psoriasis therapy [such as psoralen and ultraviolet A (PUVA) light
             therapy] or phototherapy within the previous 4 weeks; or had topical psoriasis
             treatment within the previous 2 weeks prior to randomization

          -  Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks
             prior to randomization and during the study

          -  Have participated in any study with interleukin (IL)-17 antagonists, including
             LY2439821

          -  Serious disorder or illness other than plaque psoriasis

          -  Serious infection within the last 3 months

          -  Breastfeeding or nursing (lactating) women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Benowa</city>
        <state>Queensland</state>
        <zip>4217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Woolloogabba</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 1R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B5H1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1S7K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 3H7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y6P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Z 2S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kobenhavn</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hanau</city>
        <zip>63450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hannover</city>
        <zip>30449</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mahlow</city>
        <zip>39110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Quedlinburg</city>
        <zip>06484</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wuppertal</city>
        <zip>42275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szeged</city>
        <zip>H-6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szolnok</city>
        <zip>H-5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szombathely</city>
        <zip>H-9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bologna</city>
        <zip>40100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aichi</city>
        <zip>467-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukuoka</city>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kochi</city>
        <zip>783-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kyoto</city>
        <zip>602-0841</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shiga</city>
        <zip>520-2192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shizuoka</city>
        <zip>431-3125</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tochigi</city>
        <zip>329- 0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>169-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bialystok</city>
        <zip>15-017</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lodz</city>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>04-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baia Mare</city>
        <zip>430193</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucharest</city>
        <zip>21155</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Craiova</city>
        <zip>200642</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Iasi</city>
        <zip>700125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salford</city>
        <state>Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Scunthorpe</city>
        <state>North Lincolnshire</state>
        <zip>DN15 7BH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dundee</city>
        <state>Scotland</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nuneaton</city>
        <state>Warwickshire</state>
        <zip>CV10 7BL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lanarkshire</city>
        <zip>ML6 0JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2011</study_first_submitted>
  <study_first_submitted_qc>November 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2011</study_first_posted>
  <results_first_submitted>April 20, 2016</results_first_submitted>
  <results_first_submitted_qc>April 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 27, 2016</results_first_posted>
  <disposition_first_submitted>September 29, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>September 29, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 8, 2014</disposition_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ixekizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants who received Ixekizumab (ixe) and classified as responder (Resp, sPGA 0/1) in Induction (IND) were re-randomized to receive 80 mg ixe Q4W, Q12W or placebo (PBO) in Maintenance (MAIN) [Primary Population (Pop)]. Non-responders (Non-Resp, sPGA &gt;1) in IND received 80 mg ixe Q4W, PBO Resp received PBO in MAIN (Secondary Pop).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo- Induction Period</title>
          <description>Placebo was administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W) up to Week 10.</description>
        </group>
        <group group_id="P2">
          <title>Ixe Q4W - Induction Period</title>
          <description>160 milligrams (mg) ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection every 4 weeks (Q4W). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10.</description>
        </group>
        <group group_id="P3">
          <title>Ixe Q2W - Induction Period</title>
          <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W at Weeks 4, 6, 8, and 10.</description>
        </group>
        <group group_id="P4">
          <title>Ixe/Placebo- Maintenance Period Primary Pop</title>
          <description>Participants who received 80 mg ixe Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="P5">
          <title>Ixe/Ixe Q12W - Maintenance Period Primary Pop</title>
          <description>Participants who received 80 mg ixe Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered 80 mg ixe as 1 SC injection at Week 12 followed by 80 mg ixe as 1 SC injection every 12 weeks (Q12W) up to and including Week 56.</description>
        </group>
        <group group_id="P6">
          <title>Ixe/Ixe Q4W - Maintenance Period Primary Pop</title>
          <description>Participants who received 80 mg ixe Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered 80 mg ixe as 1 SC injection at Week 12 followed by 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="P7">
          <title>Placebo Resp/Placebo - Maintenance Period Secondary Pop</title>
          <description>Participants who received Placebo during the Induction Period (Weeks 0 to 10) and classified as responders and were administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="P8">
          <title>Placebo Non-Resp/Ixe Q4W - Maintenance Period Secondary Pop</title>
          <description>Participants who received placebo in Induction Period (Weeks 0 to 10) and classified as non-responders were administered 80 mg ixe as 1 SC injection at Week 12 followed by 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="P9">
          <title>Ixe Q4W Non-Resp/Ixe Q4W- Maintenance Period Secondary Pop</title>
          <description>Participants who received 80 mg ixe Q4W in Induction Period (Weeks 0 to 10) and classified as non-responders were administered 80 mg ixe as 1 SC injection at Week 12 followed by 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="P10">
          <title>Q2W Non-Resp/Q4W - Maintenance Period Secondary Pop</title>
          <description>Participants who received 80 mg ixe Q2W in Induction Period (Weeks 0 to 10) and classified as non-responders were administered 80 mg ixe as 1 SC injection at Week 12 followed by 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="431"/>
                <participants group_id="P2" count="432"/>
                <participants group_id="P3" count="433"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="431"/>
                <participants group_id="P2" count="432"/>
                <participants group_id="P3" count="433"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="407"/>
                <participants group_id="P2" count="408"/>
                <participants group_id="P3" count="415"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="226"/>
                <participants group_id="P5" count="227">One participant withdrew end of Induction but re-randomized and treated with maintenance dose ixe.</participants>
                <participants group_id="P6" count="229"/>
                <participants group_id="P7" count="16"/>
                <participants group_id="P8" count="391"/>
                <participants group_id="P9" count="78"/>
                <participants group_id="P10" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="226"/>
                <participants group_id="P5" count="227"/>
                <participants group_id="P6" count="229"/>
                <participants group_id="P7" count="16"/>
                <participants group_id="P8" count="391"/>
                <participants group_id="P9" count="78"/>
                <participants group_id="P10" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="108"/>
                <participants group_id="P6" count="177"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="350"/>
                <participants group_id="P9" count="62"/>
                <participants group_id="P10" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="202"/>
                <participants group_id="P5" count="119"/>
                <participants group_id="P6" count="52"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="41"/>
                <participants group_id="P9" count="16"/>
                <participants group_id="P10" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Relapsed (sPGA ≥3)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="186"/>
                <participants group_id="P5" count="111"/>
                <participants group_id="P6" count="39"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="19"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical Relapse</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="11"/>
                <participants group_id="P9" count="11"/>
                <participants group_id="P10" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treated but Discontinued in Induction</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo administered as 2 SC injections Q2W up to Week 10.</description>
        </group>
        <group group_id="B2">
          <title>Ixe Q4W</title>
          <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q4W.</description>
        </group>
        <group group_id="B3">
          <title>Ixe Q2W</title>
          <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W up to Week 10.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="431"/>
            <count group_id="B2" value="432"/>
            <count group_id="B3" value="433"/>
            <count group_id="B4" value="1296"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.4" spread="13.40"/>
                    <measurement group_id="B2" value="45.6" spread="12.95"/>
                    <measurement group_id="B3" value="45.1" spread="12.40"/>
                    <measurement group_id="B4" value="45.7" spread="12.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="142"/>
                    <measurement group_id="B4" value="413"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="303"/>
                    <measurement group_id="B2" value="289"/>
                    <measurement group_id="B3" value="291"/>
                    <measurement group_id="B4" value="883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="159"/>
                    <measurement group_id="B4" value="461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Static Physician Global Assessment (sPGA)</title>
          <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>sPGA=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="197"/>
                    <measurement group_id="B3" value="231"/>
                    <measurement group_id="B4" value="632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sPGA=4, 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="202"/>
                    <measurement group_id="B4" value="664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Psoriasis Area and Severity Index (PASI)</title>
          <description>PASI combines body surface involvement in 4 regions (head, trunk, arms, and legs), percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for final PASI, calculated as: sum of severity parameters for each region*area score*weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Scores range from 0 (no Ps) to 72 (the most severe disease).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.32" spread="8.641"/>
                    <measurement group_id="B2" value="20.03" spread="7.304"/>
                    <measurement group_id="B3" value="20.09" spread="7.992"/>
                    <measurement group_id="B4" value="20.15" spread="7.992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Itch Numeric Rating Scale (NRS)</title>
          <description>The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from psoriasis (Ps) is indicated by circling the number that best describes the worst level of itching in the past 24 hours.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.0" spread="2.58"/>
                    <measurement group_id="B2" value="7.0" spread="2.50"/>
                    <measurement group_id="B3" value="7.2" spread="2.39"/>
                    <measurement group_id="B4" value="7.1" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dermatology-Specific Quality of Life Index (DLQI) Score</title>
          <description>DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered (&quot;not relevant&quot;) responses were scored as &quot;0.&quot; Total scores range from 0 to 30, with higher score indicating greater quality of life is impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.8" spread="7.11"/>
                    <measurement group_id="B2" value="13.2" spread="7.02"/>
                    <measurement group_id="B3" value="13.4" spread="7.02"/>
                    <measurement group_id="B4" value="13.1" spread="7.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nail Psoriasis Severity Index (NAPSI) (n=283, 281, 283)</title>
          <description>The NAPSI is a numeric, reproducible, objective tool to evaluate the severity of fingernail bed Ps and fingernail matrix Ps. Each fingernail is given a score for fingernail bed Ps and fingernail matrix Ps, each with scores of 0 (none) to 4 (Ps in all 4 quadrants) depending on the features of each fingernail bed and fingernail matrix Ps.The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). The sum of all fingernails equals the total NAPSI score with a range from 0 to 80. Higher scores indicated more severe psoriasis.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.9" spread="20.492"/>
                    <measurement group_id="B2" value="24.12" spread="18.243"/>
                    <measurement group_id="B3" value="24.64" spread="18.916"/>
                    <measurement group_id="B4" value="24.95" spread="19.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent of Body Surface Area (BSA) involvement of Ps</title>
          <description>BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), where 1% corresponds to the size of the participants hand (includes the palm, fingers and thumb).</description>
          <units>percent of body surface</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.4" spread="17.77"/>
                    <measurement group_id="B2" value="27.4" spread="16.20"/>
                    <measurement group_id="B3" value="28.2" spread="17.83"/>
                    <measurement group_id="B4" value="27.7" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Psoriasis Scalp Severity Index (PSSI) (n=393, 413, 393)</title>
          <description>The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (&lt;10%) to 6 (90%-100%) with a total scores range from 0 to 72, with lower scores indicating less severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.8" spread="15.70"/>
                    <measurement group_id="B2" value="19.9" spread="14.83"/>
                    <measurement group_id="B3" value="21.1" spread="14.69"/>
                    <measurement group_id="B4" value="20.9" spread="15.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quick Inventory of Depressive Symptomatology-Self Reported 16 Items (QIDS-SR16) (n=430, 431, 431)</title>
          <description>QIDS-SR16 is a participant-administered, 16-item instrument to assess the existence and severity of depression symptoms. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst). The sum of the 16 items corresponding to 9 depression domains (sad mood, concentration, self-criticism, suicidal ideation, interest, energy, sleep disturbance, change in appetite/weight, and psychomotor agitation/retardation) to give a total scores range from 0 to 27, higher scores indicate greater severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.7" spread="4.34"/>
                    <measurement group_id="B2" value="5.0" spread="4.34"/>
                    <measurement group_id="B3" value="4.5" spread="4.09"/>
                    <measurement group_id="B4" value="4.8" spread="4.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO)</title>
          <description>WPAI-PSO is a self-administered, 6-item instrument used to assess the impact of Ps on productivity impairment within the past 7 days. WPAI-PSO has 4 domains: absenteeism, presenteeism (reduced productivity at work), an overall work impairment score and impairment in daily activities performed outside work. Four scores are derived as percentages: absenteeism, presenteeism (reduced productivity while at work), overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage = each score * 100. Greater scores indicate greater impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Absenteeism (n=281, 287, 290)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.5" spread="17.07"/>
                    <measurement group_id="B2" value="4.0" spread="16.26"/>
                    <measurement group_id="B3" value="5.7" spread="19.41"/>
                    <measurement group_id="B4" value="4.7" spread="17.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity Impairment (n=431, 429, 432)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.3" spread="29.29"/>
                    <measurement group_id="B2" value="34.7" spread="28.83"/>
                    <measurement group_id="B3" value="34.2" spread="28.99"/>
                    <measurement group_id="B4" value="33.4" spread="29.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presenteeism (297, 301, 299)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.2" spread="25.85"/>
                    <measurement group_id="B2" value="25.2" spread="27.22"/>
                    <measurement group_id="B3" value="22.6" spread="26.46"/>
                    <measurement group_id="B4" value="23.3" spread="26.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work Productively Loss (n=279, 284, 288)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.6" spread="27.90"/>
                    <measurement group_id="B2" value="27.0" spread="27.90"/>
                    <measurement group_id="B3" value="24.9" spread="28.77"/>
                    <measurement group_id="B4" value="25.5" spread="28.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical Outcomes Study 36-Item Short Form (SF36) Physical component (PCS) and Mental Component (MCS)</title>
          <description>The SF-36 is a self-reported instrument that measures the participant's health status during the previous 7 days. It comprises 36-items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped in the PCS and MCS scores. Scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>PCS (n=428, 428, 432)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.92" spread="9.769"/>
                    <measurement group_id="B2" value="47.34" spread="9.169"/>
                    <measurement group_id="B3" value="46.58" spread="9.146"/>
                    <measurement group_id="B4" value="46.95" spread="9.363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS (n=428, 428, 432)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.77" spread="11.182"/>
                    <measurement group_id="B2" value="47.46" spread="11.655"/>
                    <measurement group_id="B3" value="47.94" spread="11.535"/>
                    <measurement group_id="B4" value="48.05" spread="11.463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient's Global Assessment of Disease Severity (PatGA) (n=431, 430, 430)</title>
          <description>The PatGA is a single-item self-reported instrument asking the participant to rate severity of their psoriasis &quot;today&quot; by circling a number on a 0 to 5 numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" spread="0.95"/>
                    <measurement group_id="B2" value="4.1" spread="0.88"/>
                    <measurement group_id="B3" value="4.1" spread="0.94"/>
                    <measurement group_id="B4" value="4.1" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)</title>
        <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of &quot;0&quot; or &quot;1&quot; with at least a 2-point improvement from baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>Intent to Treat (ITT) Population: all randomized participants analyzed according to the treatment to which they were assigned. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered as 2 SC injections Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O2">
            <title>Ixe Q4W</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q4W (Weeks 4 and 8).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q2W</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)</title>
          <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of &quot;0&quot; or &quot;1&quot; with at least a 2-point improvement from baseline.</description>
          <population>Intent to Treat (ITT) Population: all randomized participants analyzed according to the treatment to which they were assigned. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="432"/>
                <count group_id="O3" value="433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="76.4"/>
                    <measurement group_id="O3" value="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving ≥75% Improvement in Ps Area and Severity Index (PASI75) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis Measure: PASI)</title>
        <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>ITT Population: all randomized participants analyzed according to the treatment to which they were assigned. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for NRI analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered as 2 SC injections Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O2">
            <title>Ixe Q4W</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q4W (Weeks 4 and 8).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q2W</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving ≥75% Improvement in Ps Area and Severity Index (PASI75) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis Measure: PASI)</title>
          <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.</description>
          <population>ITT Population: all randomized participants analyzed according to the treatment to which they were assigned. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for NRI analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="432"/>
                <count group_id="O3" value="433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="82.6"/>
                    <measurement group_id="O3" value="89.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an sPGA of 0 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)</title>
        <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).</description>
        <time_frame>Week 12</time_frame>
        <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for NRI analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered as 2 SC injections Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O2">
            <title>Ixe Q4W</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q4W (Weeks 4 and 8).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q2W</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an sPGA of 0 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)</title>
          <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).</description>
          <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for NRI analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="432"/>
                <count group_id="O3" value="433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="34.5"/>
                    <measurement group_id="O3" value="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <method_desc>Due to the zero count in placebo group, p-values from Logistic Regression were not obtainable, therefore the p-value is from Fisher's exact test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <method_desc>Due to the zero count in placebo group, p-values from Logistic Regression were not obtainable, therefore the p-value is from Fisher's exact test.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving PASI 90% (PASI90) or 100% (PASI100) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: PASI)</title>
        <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI90 or PASI100 were defined as having an improvement of ≥90% or of 100% respectively in PASI scores compared to baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for NRI analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered as 2 SC injections Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O2">
            <title>Ixe Q4W</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q4W (Weeks 4 and 8).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q2W</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving PASI 90% (PASI90) or 100% (PASI100) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: PASI)</title>
          <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI90 or PASI100 were defined as having an improvement of ≥90% or of 100% respectively in PASI scores compared to baseline.</description>
          <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for NRI analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="432"/>
                <count group_id="O3" value="433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PASI90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="64.6"/>
                    <measurement group_id="O3" value="70.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="33.6"/>
                    <measurement group_id="O3" value="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for PASI90.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for PASI90.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for PASI100.</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>Due to the zero count in placebo group, p-values from Logistic Regression were not obtainable; therefore the p-value is from Fisher's exact test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for PASI100.</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>Due to the zero count in placebo group, p-values from Logistic Regression were not obtainable; therefore the p-value is from Fisher's exact test.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Maintaining sPGA 0 or 1 After Re-Randomization at Start of Maintenance Dosing Period</title>
        <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).</description>
        <time_frame>Week 60</time_frame>
        <population>Maintenance Period Primary Population (MPPP): all randomized participants from Period 2 who achieved sPGA (0, 1), were re-randomized at Week 12 and who received at least 1 dose of study treatment Period 3 period. Participants did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for NRI analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixe/Placebo</title>
            <description>Participants who received ixe (Q2W or Q4W) in Induction Period who were re-randomized at Week 12 and administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56 (Maintenance Period).</description>
          </group>
          <group group_id="O2">
            <title>Ixe/Q12W</title>
            <description>Participants who received ixe (Q2W or Q4W) in Induction Period who were re-randomized at Week 12 and were administered 80 mg ixe as 1 SC injection at Week 12 followed by 80 mg ixe as 1 SC injection Q12W up to and including Week 56 (Maintenance Period).</description>
          </group>
          <group group_id="O3">
            <title>Ixe/Q4W</title>
            <description>Participants who received ixe (Q2W or Q4W) in Induction Period who were re-randomized at Week 12 and were administered 80 mg ixe as 1 SC injection at Week 12 followed by 80 mg ixe as 1 SC injection Q4W up to and including Week 56 (Maintenance Period).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Maintaining sPGA 0 or 1 After Re-Randomization at Start of Maintenance Dosing Period</title>
          <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).</description>
          <population>Maintenance Period Primary Population (MPPP): all randomized participants from Period 2 who achieved sPGA (0, 1), were re-randomized at Week 12 and who received at least 1 dose of study treatment Period 3 period. Participants did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for NRI analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="227"/>
                <count group_id="O3" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                    <measurement group_id="O2" value="37.4"/>
                    <measurement group_id="O3" value="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression analysis included treatment and baseline weight category as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression analysis included treatment and baseline weight category as factors.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Itch Numeric Rating Scale (Itch NRS) Score ≥4 Point Reduction From Baseline</title>
        <description>The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned; and had an Itch NRS score ≥4 at baseline. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for NRI analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered as 2 SC injections Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O2">
            <title>Ixe Q4W</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q4W (Weeks 4 and 8).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q2W</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Itch Numeric Rating Scale (Itch NRS) Score ≥4 Point Reduction From Baseline</title>
          <description>The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.</description>
          <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned; and had an Itch NRS score ≥4 at baseline. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for NRI analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="379"/>
                <count group_id="O3" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5"/>
                    <measurement group_id="O2" value="80.5"/>
                    <measurement group_id="O3" value="85.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Dermatology-Specific Quality of Life Index (DLQI) Score</title>
        <description>DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered (&quot;not relevant&quot;) responses were scored as &quot;0.&quot; Total scores range from 0 to 30, with higher score indicating greater quality of life is impairment. A 5-point change from baseline is considered clinically relevant. Least squares (LS) mean change from baseline was calculated using mixed model repeated measures (MMRM).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned; and who had at least 1 post-baseline DLQI measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered as 2 SC injections Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O2">
            <title>Ixe Q4W</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q4W (Weeks 4 and 8).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q2W</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Dermatology-Specific Quality of Life Index (DLQI) Score</title>
          <description>DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered (&quot;not relevant&quot;) responses were scored as &quot;0.&quot; Total scores range from 0 to 30, with higher score indicating greater quality of life is impairment. A 5-point change from baseline is considered clinically relevant. Least squares (LS) mean change from baseline was calculated using mixed model repeated measures (MMRM).</description>
          <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned; and who had at least 1 post-baseline DLQI measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="421"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.27"/>
                    <measurement group_id="O2" value="-10.7" spread="0.27"/>
                    <measurement group_id="O3" value="-11.1" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>LS mean and P-value were calculated using MMRM with baseline score as a covariate, treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, visit and treatment-by-visit interaction as fixed effects.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>LS mean and P-value were calculated using MMRM with baseline score as a covariate, treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, visit and treatment-by-visit interaction as fixed effects.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nail Psoriasis Severity Index (NAPSI)</title>
        <description>The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail Ps. This scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants of the matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, then the sum of all fingernails equals the total NAPSI score with a range from 0 to 80 with higher scores indicating more severe psoriasis. LS mean change from baseline was calculated using MMRM.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned; and had fingernail Ps at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered as 2 SC injections Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O2">
            <title>Ixe Q4W</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q4W (Weeks 4 and 8).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q2W</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nail Psoriasis Severity Index (NAPSI)</title>
          <description>The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail Ps. This scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants of the matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, then the sum of all fingernails equals the total NAPSI score with a range from 0 to 80 with higher scores indicating more severe psoriasis. LS mean change from baseline was calculated using MMRM.</description>
          <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned; and had fingernail Ps at baseline.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="0.672"/>
                    <measurement group_id="O2" value="-7.19" spread="0.671"/>
                    <measurement group_id="O3" value="-7.24" spread="0.657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>LS mean and P-value were calculated using MMRM with baseline score as a covariate, treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, visit and treatment-by-visit interaction as fixed effects.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>LS mean and P-value were calculated using MMRM with baseline score as a covariate, treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, visit and treatment-by-visit interaction as fixed effects.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Body Surface Area (BSA) Involvement of Ps</title>
        <description>BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), where 1% corresponds to the size of the participants hand (includes the palm, fingers and thumb). Total BSA is the sum of handprints from the affected areas. LS mean change from baseline was calculated using MMRM.</description>
        <time_frame>Week 12</time_frame>
        <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned; and had at least 1 post-baseline BSA measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered as 2 SC injections Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O2">
            <title>Ixe Q4W</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q4W (Weeks 4 and 8).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q2W</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Body Surface Area (BSA) Involvement of Ps</title>
          <description>BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), where 1% corresponds to the size of the participants hand (includes the palm, fingers and thumb). Total BSA is the sum of handprints from the affected areas. LS mean change from baseline was calculated using MMRM.</description>
          <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned; and had at least 1 post-baseline BSA measurement.</population>
          <units>percentage of body surface</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="426"/>
                <count group_id="O2" value="425"/>
                <count group_id="O3" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.67"/>
                    <measurement group_id="O2" value="-21.4" spread="0.67"/>
                    <measurement group_id="O3" value="-22.4" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>LS mean and P-value were calculated using MMRM with baseline score as a covariate, treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, visit and treatment-by-visit interaction as fixed effects.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>LS mean and P-value were calculated using MMRM with baseline score as a covariate, treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, visit and treatment-by-visit interaction as fixed effects.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Psoriasis Scalp Severity Index (PSSI)</title>
        <description>The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (&lt;10%) to 6 (90%-100%) with a total scores range from 0 to 72, with lower scores indicating less severity. LS mean change from baseline was calculated using MMRM.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned; and had scalp Ps at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered as 2 SC injections Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O2">
            <title>Ixe Q4W</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q4W (Weeks 4 and 8).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q2W</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Psoriasis Scalp Severity Index (PSSI)</title>
          <description>The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (&lt;10%) to 6 (90%-100%) with a total scores range from 0 to 72, with lower scores indicating less severity. LS mean change from baseline was calculated using MMRM.</description>
          <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned; and had scalp Ps at baseline.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="393"/>
                <count group_id="O2" value="413"/>
                <count group_id="O3" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="0.53"/>
                    <measurement group_id="O2" value="-18.3" spread="0.52"/>
                    <measurement group_id="O3" value="-19.2" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>LS mean and P-value were calculated using MMRM with baseline score as a covariate, treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, visit and treatment-by-visit interaction as fixed effects.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>LS mean and P-value were calculated using MMRM with baseline score as a covariate, treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, visit and treatment-by-visit interaction as fixed effects.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO) (Quality of Life and Outcome Assessments. Measures: Participant Reported Outcomes [PRO])</title>
        <description>WPAI-PSO is a participant administered, 6-item instrument used to assess the impact of Ps on the productivity impairment within the past 7 days. WPAI-PSO has 4 domains: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism (reduced productivity while at work), overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as: each score * 100 with greater scores indicating greater impairment. LS mean change from baseline was calculated using analysis of covariance (ANCOVA).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned, and had results at specified time points, last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered as 2 SC injections Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O2">
            <title>Ixe Q4W</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q4W (Weeks 4 and 8).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q2W</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO) (Quality of Life and Outcome Assessments. Measures: Participant Reported Outcomes [PRO])</title>
          <description>WPAI-PSO is a participant administered, 6-item instrument used to assess the impact of Ps on the productivity impairment within the past 7 days. WPAI-PSO has 4 domains: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism (reduced productivity while at work), overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as: each score * 100 with greater scores indicating greater impairment. LS mean change from baseline was calculated using analysis of covariance (ANCOVA).</description>
          <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned, and had results at specified time points, last observation carried forward (LOCF).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="420"/>
                <count group_id="O2" value="417"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absenteeism (253, 250, 255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.88"/>
                    <measurement group_id="O2" value="-3.5" spread="0.87"/>
                    <measurement group_id="O3" value="-2.6" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity Impairment (420, 417, 427)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.18"/>
                    <measurement group_id="O2" value="-24.5" spread="1.18"/>
                    <measurement group_id="O3" value="-25.2" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presenteeism (275, 273, 278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.30"/>
                    <measurement group_id="O2" value="-18.8" spread="1.28"/>
                    <measurement group_id="O3" value="-18.3" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work Productivity Loss (250, 246, 252)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.40"/>
                    <measurement group_id="O2" value="-20.6" spread="1.38"/>
                    <measurement group_id="O3" value="-19.8" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline WPAI value.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>P-value is for Absenteeism.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline WPAI value.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>P-value is for absenteeism.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline WPAI value.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>P-value is for activity impairment.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline WPAI value.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>P-value is for activity impairment.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline WPAI value.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>P-value is for presenteeism.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline WPAI value.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>P-value is for presenteeism.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline WPAI value.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>P-value is for work productively loss.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline WPAI value.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>P-value is for work productively loss.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Reported 16 Items (QIDS-SR16)</title>
        <description>QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst). The sum of the 16 items corresponding to 9 depression domains [sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity. LS mean change from baseline was calculated using ANCOVA.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned, and had results at the specified time points, LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered as 2 SC injections Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O2">
            <title>Ixe Q4W</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q4W (Weeks 4 and 8).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q2W</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Reported 16 Items (QIDS-SR16)</title>
          <description>QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst). The sum of the 16 items corresponding to 9 depression domains [sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity. LS mean change from baseline was calculated using ANCOVA.</description>
          <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned, and had results at the specified time points, LOCF.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="417"/>
                <count group_id="O3" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.17"/>
                    <measurement group_id="O2" value="-1.0" spread="0.17"/>
                    <measurement group_id="O3" value="-1.3" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>LS Mean and p-values were calculated using an ANCOVA model that included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline QIDS value in the model.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>LS Mean and p-values were calculated using an ANCOVA model that included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline QIDS value in the model.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Medical Outcomes Study 36-item Short Form Health Survey (SF-36) and Physical Component Summary (PCS) and Mental Component Summary (MCS)</title>
        <description>The SF-36 is a self-reported instrument that measures the participant's health status during the previous 7 days. It comprises 36-items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped in the PCS and MCS scores. Scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean change from baseline was calculated using ANCOVA.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned; and with results at the specified time points, LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered as 2 SC injections Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O2">
            <title>Ixe Q4W</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q4W (Weeks 4 and 8).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q2W</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Medical Outcomes Study 36-item Short Form Health Survey (SF-36) and Physical Component Summary (PCS) and Mental Component Summary (MCS)</title>
          <description>The SF-36 is a self-reported instrument that measures the participant's health status during the previous 7 days. It comprises 36-items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped in the PCS and MCS scores. Scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean change from baseline was calculated using ANCOVA.</description>
          <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned; and with results at the specified time points, LOCF.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="415"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1747" spread="0.4012"/>
                    <measurement group_id="O2" value="4.3081" spread="0.3990"/>
                    <measurement group_id="O3" value="4.3159" spread="0.3878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8729" spread="0.4638"/>
                    <measurement group_id="O2" value="3.7386" spread="0.4633"/>
                    <measurement group_id="O3" value="4.1293" spread="0.4480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline SF-36 value in the model.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>P-value is for PCS.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline SF-36 value in the model.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>P-value is for PCS.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline SF-36 value in the model.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>P-value is for MCS.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The LS Mean and p-values were calculated using an ANCOVA model and included treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, and baseline SF-36 value in the model.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>P-value is for MCS.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Global Assessment of Disease Severity (PatGA)</title>
        <description>The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis &quot;today&quot; by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been). LS mean change from baseline calculated using MMRM.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned; and with at least 1 post-baseline PatGA measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered as 2 SC injections Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O2">
            <title>Ixe Q4W</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q4W (Weeks 4 and 8).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q2W</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Global Assessment of Disease Severity (PatGA)</title>
          <description>The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis &quot;today&quot; by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been). LS mean change from baseline calculated using MMRM.</description>
          <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned; and with at least 1 post-baseline PatGA measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="425"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.06"/>
                    <measurement group_id="O2" value="-3.1" spread="0.06"/>
                    <measurement group_id="O3" value="-3.2" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>LS mean and P-value were calculated using MMRM with baseline score as a covariate, treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, visit and treatment-by-visit interaction as fixed effects.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>LS mean and P-value were calculated using MMRM with baseline score as a covariate, treatment, geographic region, previous non-biologic systemic therapy, baseline weight category, visit and treatment-by-visit interaction as fixed effects.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Palmoplantar PASI (PPASI) of ≥50% (PPASI50), ≥75% (PPASI75), or 100% (PPASI100) Improvement</title>
        <description>The Palmoplantar PASI is a composite score derived from the sum of scores for erythema, induration, and desquamation [scores range from 0 (none) to 4 (very severe) for each] multiplied by the score for the extent of palm and sole area involvement [scores range from 0 (0%) to 6 (90 to100%)], with a total scores range from 0 to 72. Participants achieving PPASI50, PPASI75 or PASI100 were defined as having an improvement of at least 50%, 90%, or of 100%, respectively, in the PPASI scores compared to baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned; and who had palmoplantar Ps at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered as 2 SC injections Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O2">
            <title>Ixe Q4W</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q4W (Weeks 4 and 8).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q2W</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Palmoplantar PASI (PPASI) of ≥50% (PPASI50), ≥75% (PPASI75), or 100% (PPASI100) Improvement</title>
          <description>The Palmoplantar PASI is a composite score derived from the sum of scores for erythema, induration, and desquamation [scores range from 0 (none) to 4 (very severe) for each] multiplied by the score for the extent of palm and sole area involvement [scores range from 0 (0%) to 6 (90 to100%)], with a total scores range from 0 to 72. Participants achieving PPASI50, PPASI75 or PASI100 were defined as having an improvement of at least 50%, 90%, or of 100%, respectively, in the PPASI scores compared to baseline.</description>
          <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned; and who had palmoplantar Ps at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PPASI50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3"/>
                    <measurement group_id="O2" value="84.0"/>
                    <measurement group_id="O3" value="82.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PPASI75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3"/>
                    <measurement group_id="O2" value="74.8"/>
                    <measurement group_id="O3" value="77.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PPASI100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3"/>
                    <measurement group_id="O2" value="65.6"/>
                    <measurement group_id="O3" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for PPASI50.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for PPASI50.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for PPASI75</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for PPASI75</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for PPASI100</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value if for PPASI100.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression analysis included treatment, geographic region, previous non-biologic systemic therapy and baseline weight category as factors.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Trough Concentration at Steady State (Ctrough ss)</title>
        <time_frame>Weeks 12 and 24</time_frame>
        <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned; and who had Ctrough ss results at specified time points where the concentration met the definition of being a trough concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixe Q2W - Induction Period</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O2">
            <title>Ixe Q4W - Induction Period</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q4W (Weeks 4 and 8).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q4W - Maintenance Period</title>
            <description>80 mg ixe administered as 1 SC injection Q4W from Week 12 up to Week 60</description>
          </group>
          <group group_id="O4">
            <title>Ixe Q12W - Maintenance Period</title>
            <description>80 mg ixe administered as 1 SC injection Q12W from Week 12 up to Week 60</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Trough Concentration at Steady State (Ctrough ss)</title>
          <population>ITT Population: all randomized participants analyzed according to the treatment to which they are assigned; and who had Ctrough ss results at specified time points where the concentration met the definition of being a trough concentration.</population>
          <units>micrograms/milliliter (µg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.73" spread="79"/>
                    <measurement group_id="O2" value="2.94" spread="89"/>
                    <measurement group_id="O3" value="NA">No Induction Period results available.</measurement>
                    <measurement group_id="O4" value="NA">No Induction Period results available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No Maintenance Period results available.</measurement>
                    <measurement group_id="O2" value="NA">No Maintenance Period results available.</measurement>
                    <measurement group_id="O3" value="2.36" spread="111"/>
                    <measurement group_id="O4" value="0.281" spread="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Anti-ixekizumab Antibodies</title>
        <description>Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants * 100%.</description>
        <time_frame>Baseline through Week 12</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered as 2 SC injections Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O2">
            <title>Ixe Q4W</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q4W (Weeks 4 and 8).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q2W</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-ixekizumab Antibodies</title>
          <description>Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants * 100%.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had evaluable data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="432"/>
                <count group_id="O3" value="433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Primary Pop defined as: participants who received ixe or PBO and classified as Resp in IND and were re-randomized to ixe 80 mg Q4W, Q12W or PBO in MAIN. Secondary Pop defined as: participants who received ixe and classified as Non-Resp in IND and participants who received PBO in IND who were Resp and continued on PBO in MAIN.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo - Induction Period</title>
          <description>Placebo was administered as 2 SC injections Q2W up to Week 10.</description>
        </group>
        <group group_id="E2">
          <title>Ixe Q4W - Induction Period</title>
          <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q4W. Placebo was administered as 1 SC injection at Weeks 2, 6, and 10.</description>
        </group>
        <group group_id="E3">
          <title>Ixe Q2W - Induction Period</title>
          <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W up to Weeks 4, 6, 8 and 10.</description>
        </group>
        <group group_id="E4">
          <title>Ixe/Placebo- Maintenance Period Primary Pop</title>
          <description>Participants who received 80 mg ixe Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="E5">
          <title>Ixe/Ixe Q12W - Maintenance Period Primary Pop</title>
          <description>Participants who received 80 mg ixe Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered 80 mg ixe as 1 SC injection at Week 12 followed by 80 mg ixe as 1 SC injection Q12W up to and including Week 56.</description>
        </group>
        <group group_id="E6">
          <title>Ixe/Ixe Q4W - Maintenance Period Primary Pop</title>
          <description>Participants who received 80 mg ixe Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered 80 mg ixe as 1 SC injection at Week 12 followed by 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="E7">
          <title>Placebo Resp/Placebo - Maintenance Period Secondary Pop</title>
          <description>Participants who received Placebo during the Induction Period (Weeks 0 to 10) and classified as responders and were administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="E8">
          <title>Placebo Non-Resp/Ixe Q4W - Maintenance Period Secondary Pop</title>
          <description>Participants who received placebo in Induction Period (Weeks 0 to 10) and classified as non-responders were administered 80 mg ixe as 1 SC injection at Week 12 followed by 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="E9">
          <title>Ixe Q4W Non-Resp/Ixe Q4W - Maintenance Period Secondary Pop</title>
          <description>Participants who received 80 mg ixe Q4W in Induction Period (Weeks 0 to 10) and classified as non-responders were administered 80 mg ixe as 1 SC injection at Week 12 followed by 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="E10">
          <title>Q2W Non-Resp/Q4W - Maintenance Period Secondary Pop</title>
          <description>Participants who received 80 mg ixe Q2W in Induction Period (Weeks 0 to 10) and classified as non-responders were administered 80 mg ixe as 1 SC injection at Week 12 followed by 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="E11">
          <title>Ixe Q4W - Maintenance Period Relapse Pop</title>
          <description>Participants who relapsed (loss of response, sPGA ≥3 during Maintenance Period) were administered 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="432"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="433"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="227"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="229"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="24" subjects_at_risk="391"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E11" subjects_affected="10" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital ectopic pancreas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pancreatitis relapsing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Clostridium difficile sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Staphylococcal osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Bone contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Meralgia paraesthetica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pustular psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="432"/>
                <counts group_id="E3" subjects_affected="168" subjects_at_risk="433"/>
                <counts group_id="E4" subjects_affected="81" subjects_at_risk="226"/>
                <counts group_id="E5" subjects_affected="115" subjects_at_risk="227"/>
                <counts group_id="E6" subjects_affected="106" subjects_at_risk="229"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="210" subjects_at_risk="391"/>
                <counts group_id="E9" subjects_affected="52" subjects_at_risk="78"/>
                <counts group_id="E10" subjects_affected="35" subjects_at_risk="62"/>
                <counts group_id="E11" subjects_affected="108" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="431"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="432"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="433"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="28" subjects_affected="22" subjects_at_risk="391"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E11" events="8" subjects_affected="8" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="25" subjects_affected="18" subjects_at_risk="432"/>
                <counts group_id="E3" events="37" subjects_affected="27" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E6" events="8" subjects_affected="5" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="15" subjects_affected="13" subjects_at_risk="391"/>
                <counts group_id="E9" events="5" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="8" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="431"/>
                <counts group_id="E2" events="48" subjects_affected="26" subjects_at_risk="432"/>
                <counts group_id="E3" events="84" subjects_affected="42" subjects_at_risk="433"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E5" events="12" subjects_affected="8" subjects_at_risk="227"/>
                <counts group_id="E6" events="47" subjects_affected="12" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="94" subjects_affected="36" subjects_at_risk="391"/>
                <counts group_id="E9" events="28" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E10" events="10" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E11" events="37" subjects_affected="13" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="391"/>
                <counts group_id="E9" events="9" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="391"/>
                <counts group_id="E9" events="5" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="45" subjects_affected="41" subjects_at_risk="431"/>
                <counts group_id="E2" events="47" subjects_affected="46" subjects_at_risk="432"/>
                <counts group_id="E3" events="58" subjects_affected="50" subjects_at_risk="433"/>
                <counts group_id="E4" events="32" subjects_affected="26" subjects_at_risk="226"/>
                <counts group_id="E5" events="65" subjects_affected="41" subjects_at_risk="227"/>
                <counts group_id="E6" events="69" subjects_affected="50" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="117" subjects_affected="78" subjects_at_risk="391"/>
                <counts group_id="E9" events="24" subjects_affected="19" subjects_at_risk="78"/>
                <counts group_id="E10" events="16" subjects_affected="11" subjects_at_risk="62"/>
                <counts group_id="E11" events="44" subjects_affected="36" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="431"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="432"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E5" events="10" subjects_affected="8" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="14" subjects_affected="12" subjects_at_risk="391"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E11" events="5" subjects_affected="5" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="431"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="432"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="433"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E5" events="13" subjects_affected="11" subjects_at_risk="227"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="20" subjects_affected="18" subjects_at_risk="391"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E11" events="11" subjects_affected="11" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="431"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="432"/>
                <counts group_id="E3" events="26" subjects_affected="24" subjects_at_risk="433"/>
                <counts group_id="E4" events="25" subjects_affected="17" subjects_at_risk="226"/>
                <counts group_id="E5" events="22" subjects_affected="20" subjects_at_risk="227"/>
                <counts group_id="E6" events="20" subjects_affected="17" subjects_at_risk="229"/>
                <counts group_id="E7" events="4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E8" events="75" subjects_affected="53" subjects_at_risk="391"/>
                <counts group_id="E9" events="12" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E11" events="21" subjects_affected="18" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="431"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="432"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E6" events="10" subjects_affected="10" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="13" subjects_affected="11" subjects_at_risk="391"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E10" events="4" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E11" events="12" subjects_affected="10" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foreign body in eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="4" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Electrocardiogram qt prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="431"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="432"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="433"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E5" events="16" subjects_affected="14" subjects_at_risk="227"/>
                <counts group_id="E6" events="15" subjects_affected="12" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="18" subjects_affected="16" subjects_at_risk="391"/>
                <counts group_id="E9" events="7" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="431"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="432"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="433"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E5" events="15" subjects_affected="13" subjects_at_risk="227"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="16" subjects_affected="16" subjects_at_risk="391"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E10" events="6" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E11" events="6" subjects_affected="6" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="12" subjects_affected="8" subjects_at_risk="391"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="432"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="227"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="6" subjects_affected="4" subjects_at_risk="391"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="431"/>
                <counts group_id="E2" events="21" subjects_affected="16" subjects_at_risk="432"/>
                <counts group_id="E3" events="19" subjects_affected="18" subjects_at_risk="433"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E5" events="20" subjects_affected="17" subjects_at_risk="227"/>
                <counts group_id="E6" events="12" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="26" subjects_affected="20" subjects_at_risk="391"/>
                <counts group_id="E9" events="9" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E11" events="11" subjects_affected="6" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="431"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="432"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="433"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="227"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="11" subjects_affected="11" subjects_at_risk="391"/>
                <counts group_id="E9" events="6" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="229"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="431"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="432"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="433"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="229"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="10" subjects_affected="10" subjects_at_risk="391"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="432"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="431"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="433"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="227"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="391"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E10" events="5" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="433"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

